---
title: "Point-of-Care Testing"
---
# Point-of-Care Testing
`technology · diagnostic platform · portable biomarker detection · rapid assays · nanotechnology-enabled · clinical bedside · real-time results`

Last modified 2026-06-05 · 4 papers · 2 incoming links · 1 outgoing link

| | |
|---|---|
| **Type** | Diagnostic technology platform |
| **Core mechanism** | Rapid, portable biomarker/pathogen detection |
| **Key platforms** | [[crispr-cas12a|CRISPR/Cas12a]], aptamers, [[sers|SERS]], abiotic antibody mimics |
| **Nanotechnology basis** | Gold, silver, and polymer nanoparticles; core-shell architectures |
| **Clinical applications** | Viral diagnostics, kidney function, ICU biomarker monitoring |
| **Key sensitivity metrics** | 1×10² copies/μL ([[crispr-cas12a|CRISPR]]), 3.3 μM ([[sers|SERS]]/creatinine) |
| **Papers** | 4 indexed |
| **Incoming links** | crispr-cas12a, neurosense |

---

**Point-of-care testing (POCT)** is a diagnostic technology platform enabling rapid, sensitive detection of [[biomarkers]] and [[pathogens]] directly at the clinical bedside with minimal equipment requirements and real-time or near real-time reporting. The field has undergone transformative advancement through integration of diverse molecular and biosensing platforms, including [[crispr-cas12a|CRISPR/Cas12a]]-based nucleic acid detection, electrochemical aptamer-based biosensors, and surface-enhanced Raman scattering ([[sers|SERS]]) approaches, all underpinned by nanotechnology substrates employing gold, silver, and synthetic polymer nanoparticles. These innovations collectively address critical clinical unmet needs spanning viral pandemic response, real-time kidney function assessment, and continuous [[intensive-care-unit|intensive care unit (ICU)]] biomarker surveillance, fundamentally reshaping the speed and accessibility of clinical decision-making.

---

## Mechanism

POCT operates on the principle of achieving high analytical sensitivity while maintaining operational simplicity—a balance historically difficult to achieve outside centralized laboratory settings. The foundational innovation across contemporary POCT platforms is the strategic deployment of [[nanotechnology|nanoparticles]] as signal amplification and substrate elements. Core-shell nanoparticle architectures, particularly gold-core structures functionalized with metal shells or polymeric coatings, provide multiple advantages: enhanced optical properties enabling detection at sub-micromolar concentrations, increased surface-area-to-volume ratios for probe immobilization, and reduced matrix interference in biological samples.¹ The integration of [[crispr-cas12a|CRISPR/Cas12a]] into rapid isothermal amplification workflows exemplifies this approach—rational molecular design of CRISPR RNA (crRNA) target complementarity allows simultaneous elimination of cis-cleavage artifacts while preserving robust trans-cleavage activity, enabling single-tube reaction formats that directly address POCT workflow simplification.¹

---

## Nucleic acid detection platforms

[[crispr-cas12a|CRISPR/Cas12a]]-based POCT assays have emerged as a leading modality for pathogen detection due to their combinatorial sensitivity, sequence discrimination capability, and molecular programmability. The one-pot RPA-CRISPR system—integrating recombinase polymerase amplification with CRISPR detection—achieves a limit of detection of 1×10² copies/μL while simultaneously discriminating single-nucleotide polymorphisms across a 200 bp target range.¹ This dual capability of high sensitivity and precise genomic discrimination is particularly valuable in pandemic response scenarios and surveillance of antimicrobial-resistant pathogens. The assay successfully transitioned from proof-of-concept to biological validation in Salmonella and avian leukosis virus detection, demonstrating that rational crRNA design—specifically shortening the duplex region between crRNA and target while maintaining complementarity through single-stranded DNA extensions—effectively abolishes non-specific cis-cleavage while preserving the clinically essential trans-cleavage activity required for optical signal generation.

---

## CSF biomarker and physical parameter monitoring

The [[neurosense|NeuroSense]] platform exemplifies POCT integration into the [[intensive-care-unit|intensive care unit]] setting by addressing a specific clinical bottleneck: real-time monitoring of cerebrospinal fluid (CSF) composition and flow dynamics in patients with [[external-ventricular-drainage|external ventricular drainage systems]].² Rather than relying on intermittent manual sampling—which introduces diagnostic delays in detecting infection or mechanical malfunction—NeuroSense employs a multiplexed electrochemical biosensing architecture. The platform incorporates [[aptamer|aptamer]]-based glucose and lactate sensors leveraging electrochemical transduction, a polydopamine-derived pH sensor, and an impedance-based flow sensor, enabling simultaneous measurement of four independent parameters critical to infection detection and drainage assessment.² Clinical validation in hospitalized ICU patients demonstrated strong correlation with reference laboratory standards, establishing the platform's reliability across real biological matrices and clinical workflows. This integrated approach demonstrates that POCT need not be confined to simple binary detection but can achieve multiplexed, quantitative biomarker surveillance comparable to centralized laboratory capacity while maintaining the speed advantage essential for acute care decision-making.

---

## Kidney function assessment and SERS-based serum biomarkers

Serum creatinine monitoring represents a clinically crucial but technically challenging POCT application. Traditional commercial kits employing creatinine kinase methods suffer from matrix interference—the non-specific binding of serum proteins and organic components to detection substrates—that compromises accuracy in complex biological fluids. pH-assisted surface-enhanced Raman scattering ([[sers|SERS]]) overcomes this limitation through a combination of rational pH optimization and [[nanotechnology|nanoparticle]] architecture refinement.³ Core-shell Au@MPA@Ag nanoparticles (gold core with 3-mercaptopropionic acid linker and silver shell) exhibit dramatically enhanced SERS response when creatinine adsorption is promoted under alkaline conditions (pH 9), enabling a limit of detection of 3.3 μM with recovery rates of 98–107% in human serum.³ This quantitative accuracy—validated against reference laboratory assays—demonstrates that POCT methodologies can achieve the precision required for continuous clinical monitoring of kidney function, addressing the critical need for early detection of acute kidney injury in both ambulatory and hospital-based settings.

---

## Abiotic antibody mimics and viral antigen detection

A paradigmatic innovation in POCT architecture is the development of abiotic antibody mimics—synthetic polymer nanoparticles engineered to replicate antibody binding specificity without requiring biological scaffolds. Hydrogel polymer nanoparticles derived from aromatic amino acid monomers (particularly N-acryloyl-L-tryptophan) achieve binding efficacy and epitope specificity comparable to monoclonal antibodies for [[sars-cov-2|SARS-CoV-2]] spike antigens while offering advantages in thermal stability, manufacturability, and cost.⁴ Integration of these abiotic probes with gold nanoparticles through in situ polymerization generates core-shell Au@polymer nanoprobes suitable for lateral flow immunoassay formats, enabling rapid visual detection of viral antigens without requiring external instrumentation or biomolecule-based capture elements.⁴ The mechanistic advantage derives from synergistic steric and electrostatic interactions: the spatial arrangement of anionic carboxyl groups and aromatic indolyl residues within the polymer matrix directly mirrors key binding epitopes of the spike receptor binding domain, enabling competitive inhibition of natural [[ace2|ACE2]] receptor interactions. This biomolecule-free approach addresses a persistent POCT challenge—the scalability and stability limitations of antibody production—while maintaining the diagnostic performance required for pandemic surveillance.

---

## Clinical validation and standards correlation

Across all contemporary POCT platforms—from [[crispr-cas12a|CRISPR/Cas12a]] nucleic acid assays to [[sers|SERS]]-based biomarker quantification to [[neurosense|NeuroSense]] multiplexed sensing—strong correlation with centralized laboratory reference standards has been demonstrated across diverse biological matrices including serum, cerebrospinal fluid, and simulated clinical conditions.²³⁴ This validation establishes POCT not merely as a convenience technology but as an analytically rigorous platform capable of delivering clinically actionable results at the point of care. The combination of rational molecular design (exemplified by CRISPR crRNA engineering and abiotic antibody optimization), [[nanotechnology|nanoparticle]] substrate innovation, and rigorous clinical evaluation has collectively advanced POCT from a research paradigm to deployable clinical infrastructure addressing unmet diagnostic needs in pandemic response, intensive care management, and chronic disease monitoring.

---

## References
1. PMID:42065492 — Sensitive and robust one-pot RPA-CRISPR/Cas12a assay with elimination of cis-cleavage
2. PMID:42127221 — A platform for near real-time and multiplexed monitoring of cerebrospinal fluid biomarkers and flow in neurocritical care
3. PMID:41570416 — pH-assisted ratiometric surface-enhanced Raman scattering for reliable creatinine quantification in serum
4. PMID:41478048 — Engineering an abiotic antibody mimic: Structural and molecular mechanisms for targeting, neutralizing, and point-of-care testing virus antigens